GreenLight Biosciences Holdings, PBC (GRNA)

NASDAQ: GRNA · IEX Real-Time Price · USD
-0.18 (-2.44%)
May 25, 2022 4:30 PM EDT - Market closed
Market Cap887.03M
Revenue (ttm)1.85M
Net Income (ttm)-169.01M
Shares Out123.20M
EPS (ttm)-18.50
PE Ration/a
Forward PEn/a
Ex-Dividend Daten/a
Previous Close7.38
Day's Range7.14 - 7.47
52-Week Range4.83 - 15.80
Price Targetn/a
Earnings Daten/a

About GRNA

GreenLight Biosciences Holdings, a biotechnology company, manufactures and sells ribonucleic acid (RNA) products for human health and agriculture applications. Its products for human health include mRNA vaccines and therapeutics; and agricultural RNA products to protect honeybees and crops. The company was founded in 2008 and is headquartered in Medford, Massachusetts.

Stock ExchangeNASDAQ
Ticker SymbolGRNA
Full Company Profile

Financial Performance

In 2021, GRNA's revenue was $1.60 million, a decrease of -8.70% compared to the previous year's $1.75 million. Losses were -$112.31 million, 110.9% more than in 2020.

Financial Statements


GreenLight's honeybee-saving RNA solution named finalist in World Changing Ideas Award

BOSTON, May 10, 2022 (GLOBE NEWSWIRE) -- An RNA-based solution by GreenLight Biosciences designed to protect honeybees from the Varroa destructor mite was named a finalist by Fast Company for its 2022 W...

2 weeks ago - GlobeNewsWire

Co-developer of COVID-19 Vaccine Joins GreenLight Advisory Board

BOSTON, March 29, 2022 (GLOBE NEWSWIRE) -- GreenLight Biosciences, PBC, a biotechnology company focused on RNA research, product design, development, and manufacturing for human, animal, and plant healt...

1 month ago - GlobeNewsWire

GreenLight Biosciences Holdings, PBC (GRNA) enters into multitarget licensing agreement with Serum Institute of India...

BOSTON and PUNE, India, March 14, 2022 (GLOBE NEWSWIRE) -- GreenLight Biosciences Holdings PBC today announced a licensing agreement with Serum Institute of India, Pvt, Ltd., aimed at accelerating acces...

2 months ago - GlobeNewsWire

Environmental Impact Acquisition Corporation approval obtained; GreenLight Biosciences set to begin trading under Nas...

BOSTON, Feb. 2, 2022 /PRNewswire/ -- Environmental Impact Acquisition Corporation (NASDAQ: ENVI), a publicly-traded special purpose acquisition company, announced today that its business combination wit...

3 months ago - PRNewsWire

GreenLight Biosciences and Germains Seed Technology Partner to Explore Development of World's First dsRNA Seed Treatm...

BOSTON, Jan. 31, 2022 /PRNewswire/ -- GreenLight Biosciences and Germains Seed Technology, an industry leader in seed treatment technologies, today announced a research partnership agreement that could ...

3 months ago - PRNewsWire

ENVI Announces Quorum to Pass Business Combination With GreenLight Biosciences and Achievement of All Transaction Req...

BOSTON, Jan. 28, 2022 /PRNewswire/ -- Environmental Impact Acquisition Corporation ("ENVI" or the "Company") (Nasdaq: ENVI) today announced that it had achieved a quorum for the special meeting of its s...

3 months ago - PRNewsWire

ENVI and GreenLight Biosciences Announce Filing of Definitive Proxy Statement/Prospectus and the February 1st, 2022 S...

BOSTON, Jan. 14, 2022 /PRNewswire/ -- Environmental Impact Acquisition Corporation (NASDAQ: ENVI) ("ENVI"), a publicly-traded special purpose acquisition company, announced today that ENVI's definitive ...

4 months ago - PRNewsWire

GreenLight Biosciences (ENVI) partners with IAVI to accelerate COVID-19 vaccine trial in Africa

NEW YORK, Nov. 30, 2021 /PRNewswire/ -- GreenLight Biosciences has partnered with the non-profit scientific research organization IAVI to work together on a Phase I clinical trial in Africa. IAVI and it...

5 months ago - PRNewsWire

GreenLight Biosciences and Samsung Biologics announce collaboration to build capacity for messenger RNA Vaccine Manuf...

BOSTON and INCHEON, South Korea, Nov. 24, 2021 /PRNewswire/ -- GreenLight Biosciences (Nasdaq: ENVI), a biotechnology company dedicated to making ribonucleic acid (RNA) products affordable and accessibl...

6 months ago - PRNewsWire

Serum Life Sciences invests in RNA biotech GreenLight by joining expanded financing for Environmental Impact Acquisit...

BOSTON, Nov. 23, 2021 /PRNewswire/ -- GreenLight Biosciences Inc., an RNA-focused biotech ("GreenLight"), and Environmental Impact Acquisition Corp. (Nasdaq: ENVI) today announced an expansion of its PI...

6 months ago - PRNewsWire

Greenlight Biosciences (ENVI) Adds Two World-Renowned Scientists To Its Scientific Advisory Board

BOSTON, Nov. 4, 2021 /PRNewswire/ -- GreenLight Biosciences is delighted to announce the appointment of Professor Diane E. Griffin, MD, PhD, and Emmanuel Hanon, DVM, PhD, to its Human Health Scientific ...

6 months ago - PRNewsWire

GreenLight Biosciences opens RNA production facility for the next generation of agricultural products

ROCHESTER, N.Y., Sept. 22, 2021 /PRNewswire/ -- GreenLight Biosciences, Inc., a biotechnology company focused on RNA research, design, and manufacturing for human, animal, and plant health, announced th...

8 months ago - PRNewsWire

RNA Tech Vaccine Developer GreenLight Biosciences Riding To NASDAQ Debut Via $1.5B SPAC Deal

GreenLight Biosciences Inc is combining with a special-purpose acquisition company to go public in a deal that values the RNA-technology firm at about $1.5 billion. GreenLight is merging with Environmen...

9 months ago - Benzinga

Vaccine developer GreenLight is going public in a $1.5 billion SPAC deal

As some high-profile SPACs have imploded or fallen afoul of regulators, investors have increasingly shied away from the space.

9 months ago - Business Insider

GreenLight Biosciences Announces Business Agreement With Environmental Impact Acquisition Corp. to Become Publicly Tr...

BOSTON--(BUSINESS WIRE)--GreenLight Biosciences announces business agreement with Environmental Impact Acquisition Corp. to become publicly traded company

9 months ago - Business Wire